This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

10 Most Shorted Stocks in Biotech

Stocks in this article: SVNT AVNR BPAX VVUS SGEN ONTY SQNM

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Seattle Genetics (SGEN - Get Report)

Short interest: 26%
52-week high: $19.42
Current price: $19.04
Year-to-date performance relative to the Nasdaq Biotechnology Index: Up 27%

The market opportunity for the newly launched Adcetris in relapsed and refractory Hodgkin's lymphoma is much smaller than Seattle Genetics' executives and bullish analysts forecast. Recent sell-side surveys of lymphoma doctors claim to have found enough eligible patients to predict a successful Adcetris launch. These reports have helped Seattle Genetics' stock price recover from the August lows following the market collapse. Hedge-fund shorts have done doctor surveys of their own which reveal the opposite -- too few Hodgkin's patients -- and they're betting that Seattle Genetics' stock price will fall again.

Even if Seattle Genetics puts up early strong Adcetris sales numbers in the third and fourth quarters, it will be more likely due to inventory stocking and a backlog of advanced Hodgkin's patients who were waiting for treatment. Once that initial bolus of patients is treated, Adcetris sales will fall off a cliff. And moving Adcetris into earlier-stage Hodgkin's will be very difficult because the standard drug therapy used today is already highly effective, with response rates hovering near 90%.

Shorts also point to Seattle Genetics' decision to prevent distributors from reporting monthly Adcetris sales figures to IMS Health as a red flag suggesting the company is nervous about the drug's commercial trajectory.

4 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs